Of the 3,347 Americans waiting for a donor heart in 2022, only 810 received one — which explains why so many eyes were on Griffith’s groundbreaking operation last January to give end-stage heart failure patient David Bennett a whole heart from a genetically engineered pig. Thanks to novel immunosuppressants and gene-editing of the donor animal by the biotech Revivicor, which was acquired by United Therapeutics in 2011, the transplant was initially successful, with no signs of rejection. Although Bennett died two months after the surgery, the experiment has been hailed as an important step in the field of transplantation. If the FDA authorizes Griffith’s application for future trials, his work could make further progress in addressing the shortage of donor organs.
Bartley Griffith
Director, Cardiac and Lung Transplant Programs, University of Maryland Medical Center
More in Medicine
Medicine
Toyin Ajayi
Co-founder and CEO, Cityblock Health
Medicine
Abigail Echo-Hawk
Director, Urban Indian Health Institute
Medicine
Jesse M. Ehrenfeld
President-elect, American Medical Association
Medicine
Selwyn M. Vickers
President and CEO, Memorial Sloan Kettering Cancer Center
Medicine
Robert Winn
Director, Virginia Commonwealth University Massey Cancer Center